Fernanda I Staquicini
Overview
Explore the profile of Fernanda I Staquicini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Staquicini D, Cardo-Vila M, Rotolo J, Staquicini F, Tang F, Smith T, et al.
Proc Natl Acad Sci U S A
. 2023 Aug;
120(34):e2220269120.
PMID: 37579172
The vascular endothelium from individual organs is functionally specialized, and it displays a unique set of accessible molecular targets. These serve as endothelial cell receptors to affinity ligands. To date,...
2.
Sillerud L, Neuwelt A, Staquicini F, Arap W, Pasqualini R
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359704
Tumor-associated macrophages (TAMs) in breast cancer regulate inflammation, immunosuppression, angiogenesis, and metastasis. However, TAM imaging remains a clinical challenge. Ferumoxytol has long been an FDA-approved superparamagnetic iron oxide nanoparticle (SPION)...
3.
Staquicini D, Tang F, Markosian C, Yao V, Staquicini F, Dodero-Rojas E, et al.
Proc Natl Acad Sci U S A
. 2021 Jul;
118(30).
PMID: 34234013
Development of effective vaccines against coronavirus disease 2019 (COVID-19) is a global imperative. Rapid immunization of the entire human population against a widespread, continually evolving, and highly pathogenic virus is...
4.
Staquicini F, Hajitou A, Driessen W, Proneth B, Cardo-Vila M, Staquicini D, et al.
Elife
. 2021 Jun;
10.
PMID: 34060472
Triple-negative breast cancer (TNBC) is an aggressive tumor with limited treatment options and poor prognosis. We applied the in vivo phage display technology to isolate peptides homing to the immunosuppressive...
5.
Staquicini D, Barbu E, Zemans R, Dray B, Staquicini F, Dogra P, et al.
Med
. 2021 Apr;
2(3):321-342.
PMID: 33870243
Background: The extensive alveolar capillary network of the lungs is an attractive route for administration of several agents. One key functional attribute is the rapid onset of systemic action due...
6.
Staquicini D, Tang F, Markosian C, Yao V, Staquicini F, Dodero-Rojas E, et al.
bioRxiv
. 2021 Mar;
PMID: 33758865
Significance: The ongoing COVID-19 global pandemic has accounted for over 2.5 million deaths and an unprecedented impact on the health of mankind worldwide. Over the past several months, while a...
7.
Tang F, Davis D, Arap W, Pasqualini R, Staquicini F
Adv Cancer Res
. 2020 Jun;
147:303-317.
PMID: 32593404
Receptor tyrosine kinases (RTKs) are integral membrane sensors that govern cell differentiation, proliferation and mobility, and enable rapid communication between cells and their environment. Of the 20 RTK subfamilies currently...
8.
Staquicini F, Smith T, Tang F, Gelovani J, Giordano R, Libutti S, et al.
Cancer Gene Ther
. 2019 May;
27(5):301-310.
PMID: 31130731
Glioblastoma persists as a uniformly deadly diagnosis for patients and effective therapeutic options are gravely needed. Recently, targeted gene therapy approaches are reemerging as attractive experimental clinical agents. Our ligand-directed...
9.
Tang F, Staquicini F, Teixeira A, Michaloski J, Namiyama G, Taniwaki N, et al.
Proc Natl Acad Sci U S A
. 2019 Jan;
116(6):2300-2305.
PMID: 30670660
Endothelial heterogeneity has important implications in health and disease. Molecular markers selectively expressed in the vasculature of different organs and tissues are currently being explored in targeted therapies with promising...
10.
DAngelo S, Staquicini F, Ferrara F, Staquicini D, Sharma G, Tarleton C, et al.
JCI Insight
. 2018 May;
3(9).
PMID: 29720567
We developed a potentially novel and robust antibody discovery methodology, termed selection of phage-displayed accessible recombinant targeted antibodies (SPARTA). This combines an in vitro screening step of a naive human...